MED at a glance
MEDIFAST INC (MED, SEC CIK 910329) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on August 3, 2026 and Form 4 insider filings as recently as September 30, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), MEDIFAST INC (MED) reported revenue of $385.8 million (down 36.0% from FY2024) and a net loss of $18.7 million. Diluted EPS was -$1.70.
- As of June 30, 2026, 22 institutional investment managers tracked by SignalX reported holding MEDIFAST INC (MED) shares worth $39.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Chard Daniel R on September 29, 2026 of 9,544 shares at $11.73 per share.
- In the last 90 days, MED insiders reported 8 open-market purchases ($1.4M) and 2 open-market sales ($226K) on Form 4, a net purchase of $1.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $385.8M
- −36.0% vs prior year
- Insiders · 90 days
- 8 buys · 2 sells
- Net +$1.2M
- 13F holders
- 22 funds
- $39.8M · +1 vs prior quarter
- Latest 8-K
- Aug 3, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $76.4M, down 27.6% YoY from $105.6M, driven by active earning coaches falling to 11,700 from 22,800
- Gross margin 69.9% vs 72.6% YoY; operating margin (5.7%) vs (1.0%)
- Average revenue per active coach $6,529, up 41.0% from $4,630
- Active earning coaches expected to continue declining in 2026 amid GLP-1 adoption and client-acquisition pressure
- Trilivy Reset Fueling line launched; updated product line expected fully marketed this quarter
Risk Factors
- No Risk Factors section provided; supplied text covers equity repurchases, trading arrangements, and exhibits
- Repurchase-plan risk: 1,323,568 shares remained eligible, with timing and pricing dependent on market conditions
- Insider-trading disclosure: Chairman Daniel R. Chard adopted a Rule 10b5-1 arrangement for up to 19,089 shares
- Governance flexibility: Board may modify or terminate the Stock Repurchase Plan at any time
AI summary of the MED 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 FY2026 earnings released August 3, 2026, covering the quarter ended June 30, 2026
- Detailed financial results and management commentary contained in Exhibit 99.1
Item 7.01: Regulation FD Disclosure
- OPTAVIA rebranded as Trilivy, repositioning Medifast’s wholly owned lifestyle brand around comprehensive metabolic health
- Strategic shift broadens brand positioning beyond traditional weight management toward an integrated metabolic-health offering
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Chief Legal Officer and Corporate Secretary Jason L. Groves resigned effective May 29, 2026
- Departure unrelated to disagreements or operational, policy, or practice issues
AI summaries of MED 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MED
Don't miss the next MED filing
- Alerts as it files. A push when MED files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MED, by share count.
- Ask anything. An AI agent that reads every MED filing and answers with sources.
MED alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Chard Daniel R | Sell | Sep 29, 2026 | 9,544 | $11.73 |
| Chard Daniel R | Sell | Sep 28, 2026 | 9,545 | $11.98 |
| Kiai Parsa | Buy | Aug 26, 2026 | 41,975 | $12.26 |
| Kiai Parsa | Buy | Aug 26, 2026 | 1,175 | $12.26 |
| Kiai Parsa | Buy | Aug 24, 2026 | 118 | $12.00 |
| Kiai Parsa | Buy | Aug 24, 2026 | 4,211 | $12.00 |
| Kiai Parsa | Buy | Aug 20, 2026 | 1,175 | $11.60 |
| Kiai Parsa | Buy | Aug 20, 2026 | 41,975 | $11.60 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $602.5M | $385.8M |
| Gross Profit | - | $444.6M | $275.2M |
| Operating Income | - | $2.9M | -$14.2M |
| Net Income | - | $2.1M | -$18.7M |
| Gross Margin | - | 73.8% | 71.3% |
| Op. Margin | - | 0.5% | -3.7% |
| Net Margin | - | 0.3% | -4.8% |
| Balance Sheet | |||
| Total Assets | $309.9M | $284.2M | $248.0M |
| Equity | $201.5M | $210.1M | $198.9M |
| ROE | - | 1.0% | -9.4% |
| Per Share | |||
| EPS | - | $0.19 | $-1.70 |
| Cash Flow | |||
| Operating CF | - | $24.5M | $6.9M |
| CapEx | - | $7.5M | $5.6M |
Source: XBRL data in MEDIFAST INC (MED)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate MED share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 22 | $39.8M |
| Q1 2026 | 21 | $45.3M |
| Q4 2025 | 22 | $52.1M |
| Q3 2025 | 22 | $78.7M |
| Q2 2025 | 25 | $77.9M |
| Q1 2025 | 20 | $56.8M |
| Q4 2024 | 18 | $62.9M |
| Q3 2024 | 16 | $58.9M |
- Two Sigma Investments+143.2K (+42%)
- AQR Capital Management+90.9K (+62%)
- Goldman Sachs Group+89.9K (+59%)
- T. Rowe Price Group+5.7K (+21%)
- JPMorgan Chase & Co+5.3K (+6%)
- BlackRock−575.0K (-61%)
- Vanguard Portfolio Management LLC−173.7K (-86%)
- State Street Corp−170.3K (-77%)
- D.E. Shaw & Co−68.2K (-42%)
- Northern Trust−64.8K (-70%)
- Citadel Advisors LLC+56.4K
- Millennium Management+47.9K
- Fifth Third Bancorp+48
- BNY Mellon−34.3K
- Citigroup−3.6K
Source: 13F-HR filings on SEC EDGAR (aggregated from 166 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MED filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Sep 30, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 26, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 8-K | Jul 17, 2026 | - | Analysis | - |
| 8-K | Jun 1, 2026 | - | Analysis | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 28, 2026 | - | - | |
| 8-K | May 26, 2026 | - | Analysis | |
| SC 13G | May 15, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 8-K | May 4, 2026 | - | Analysis | - |
| 10-Q | May 4, 2026 | Mar 31, 2026 | Analysis | |
| 4 | Mar 27, 2026 | - | - | - |
| 4 | Mar 27, 2026 | - | - | - |
| 4 | Mar 27, 2026 | - | - | - |
| SC 13D | Mar 20, 2026 | - | - | |
| 8-K | Mar 20, 2026 | - | - | - |
Related Consumer Staples companies
- MKC · McCormick & CompanyMiscellaneous Food Preparations & Kindred Products
- UTZ · Utz Brands, Inc.Miscellaneous Food Preparations & Kindred Products
- ACI · Albertsons Companies IncRetail-Grocery Stores
- MO · AltriaCigarettes
- ANDE · Andersons, Inc.Wholesale-Farm Product Raw Materials
- BUD · Anheuser-Busch InBev SA/NVMalt Beverages
- ADM · Archer Daniels MidlandFats & Oils
- ARKO · ARKO Corp.Retail-Convenience Stores
MED SEC filings: frequently asked questions
Are MED insiders buying or selling?
In the last 90 days, MEDIFAST INC (MED) officers, directors and 10% owners reported 8 open-market purchases worth $1.4 million by 1 insider and 2 open-market sales worth $226,289 by 1 insider on Form 4, a net purchase of $1.2 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MED stock?
As of June 30, 2026, the largest MEDIFAST INC (MED) holders among the 13F filers tracked by SignalX were Renaissance Technologies LLC ($8.3 million), Two Sigma Investments ($5.1 million), Vanguard Capital Management LLC ($4.7 million), BlackRock ($3.9 million), Dimensional Fund Advisors ($3.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MED's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), MEDIFAST INC (MED) reported revenue of $385.8 million (down 36.0% from FY2024) and a net loss of $18.7 million. Diluted EPS was -$1.70. The figures come from the XBRL data in the 10-K.
What did MED report in its latest 8-K?
MEDIFAST INC (MED) filed an 8-K on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 FY2026 earnings released August 3, 2026, covering the quarter ended June 30, 2026.
What are the latest MED SEC filings?
MEDIFAST INC (MED) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on August 3, 2026 and a Form 4 insider filing on September 30, 2026.
What is MED's SEC CIK number?
MEDIFAST INC (MED)'s SEC Central Index Key (CIK) is 910329. EDGAR lists every MED filing under that number.
Ask anything about MED
The research agent reads MED's filings, financials, insider trades and 13F holders, then answers with sources.